Key result
Non-adherence to PAH therapies linked to ~133% higher mortality risk in PDE5i-treated patients.
Why the study?
Although new medications have improved outcomes in pulmonary arterial hypertension, adherence is crucial, prompting evaluation of adherence patterns, associated factors, and impact on clinical outcomes.
Does non-adherence to PAH-specific therapies worsen clinical outcomes in patients with pulmonary arterial hypertension?
Cohort (n=7,496)
Does non-adherence to PAH-specific therapies worsen clinical outcomes in patients with pulmonary arterial hypertension?
Hazard Ratio: 2.33 (95% CI 1.79–3.03)
p-value: p=<0.001
Non-adherence to PAH-specific therapies is associated with a significantly increased risk of mortality, highlighting the critical need for adherence-improving strategies.
Non-adherence may raise mortality risk in PAH; hypothesis-generating for adherence interventions, needing randomized confirmation.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive disease with significant morbidity and mortality. New medications have improved outcomes, but adherence is crucial. OBJECTIVE: Exploring adherence to PAH-specific therapies across therapeutic classes, we identified factors associated with non-adherence and evaluated its impact on clinical outcomes. METHODS: Using claims from the Komodo Research Database, we identified patients initiating therapy with phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulators, or prostacyclin pathway agents (PPA) between January 2017 and June 2022. Adherence was measured by proportion of days covered (PDC) during the treatment period, defined as 60 days after first therapy until treatment discontinuation/censor. Non-adherence was defined as PDC <80 %. Clinical outcomes were assessed during the treatment period. Stepwise Cox proportional-hazard models identified predictors of non-adherence and its impact on outcomes within treatment groups. RESULTS: Among 7496 patients, index treatment distributions were 56.6 % PDE5i, 25.9 % ERA, 6.6 % PPA injectable, 4.7 % PPA inhaled, 3.3 % PPA oral, and 2.9 % sGC stimulators. Mean PDC was high across all treatment groups (>90 %); non-adherence was highest with PDE5i (17.0 %) and inhaled PPA (15.3 %). Factors associated with non-adherence varied by drug class. Non-adherence was significantly associated with worse clinical outcomes: in the PDE5i group, risk of mortality more than doubled with non-adherence (HR 2.33 [95 % CI 1.79-3.03]; p < 0.001), and increased more than fivefold in the ERA group (5.43 [3.33-8.85]; p < 0.001). CONCLUSIONS: Non-adherence to PAH therapy is associated with poor clinical outcomes. Strategies to improve adherence are crucial to optimizing patient outcomes.
No takes yet. Share an insight, caveat, or question.
T et al. (2026) conducted a cohort in Pulmonary arterial hypertension (PAH) (n=7,496). Non-adherence to PAH-specific therapies (PDC <80%) vs. Adherence to PAH-specific therapies (PDC ≥80%) was evaluated on Mortality (PDE5i group) (HR 2.33, 95% CI 1.79-3.03, p=<0.001). Non-adherence to PAH therapies significantly increased mortality risk, with a 2.33-fold increase in the PDE5i group (95% CI 1.79-3.03) and a 5.43-fold increase in the ERA group (95% CI 3.33-8.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: